PE-22-28: The Spadin-Derived Peptide for Depression, Cognition, and Neuroprotection

What Exactly Is PE-22-28?

PE-22-28 is a truncated, optimized analogue of spadin, itself an endogenous peptide released by cleavage of the sortilin propeptide. Spadin was first characterized by Mazella and colleagues as a natural antidepressant acting on the TREK-1 channel. PE-22-28 was engineered to retain that core pharmacology in a shorter, more blood-brain-barrier-permeable sequence of eight amino acids. The parent compound spadin contains 17 residues; reducing the chain to eight improved central nervous system penetration without losing channel-blocking potency in cell-based assays.

TREK-1 (TWIK-related potassium channel 1, gene symbol KCNK2) is a two-pore-domain background potassium channel expressed heavily in hippocampal pyramidal neurons, prefrontal cortical layers II through IV, and dorsal raphe serotonergic nuclei. When TREK-1 is open, it hyperpolarizes the neuron, dampening serotonergic and noradrenergic firing. TREK-1 knockout mice display a phenotype that mirrors pharmacological antidepressant treatment: elevated serotonin turnover, resistance to forced-swim despair, and enhanced hippocampal long-term potentiation. Lesage F et al., 2000 described the channel's distribution. By blocking TREK-1, PE-22-28 replicates that knockout state without genetic manipulation.

Spadin's initial characterization as an endogenous antidepressant peptide appeared in a 2010 paper by Mazella et al. showing that peripheral injection reversed depressive behavior in mice within four days, considerably faster than standard SSRI timelines in the same forced-swim and tail-suspension assays. That foundational study is indexed at PubMed. PE-22-28 was subsequently developed to improve on spadin's short plasma half-life, which is estimated at roughly 30 minutes due to rapid peptidase degradation.

How PE-22-28 Blocks TREK-1 and Why That Matters Clinically

The two-pore-domain family of potassium channels differs from voltage-gated channels in that it remains partially open at rest, setting the neuron's resting membrane potential. TREK-1 is particularly sensitive to arachidonic acid, lysophospholipids, stretch, and temperature changes, making it a convergence point for stress signals. Chronic stress elevates glucocorticoids, which upregulate TREK-1 expression in hippocampal CA1 neurons, pulling the resting potential toward hyperpolarization and reducing the probability that serotonin or norepinephrine release produces a postsynaptic action potential.

PE-22-28 binds to the extracellular loop of TREK-1 at nanomolar concentrations, occluding the channel and shifting membrane potential back toward threshold. In hippocampal slice recordings from C57BL/6 mice, acute TREK-1 blockade increased the firing frequency of CA1 pyramidal cells by roughly 40% compared to vehicle, an effect blocked by the selective TREK-1 agonist ML67-33. Critically, the same blockade increased hippocampal BDNF protein levels by approximately 2.3-fold over 72 hours, an observation relevant to both mood and memory consolidation. BDNF's role in depression is reviewed extensively in NIMH-funded work indexed at PubMed.

Serotonin synthesis depends partly on adequate tryptophan hydroxylase activity in raphe neurons, and TREK-1 hyperpolarization suppresses that activity. PE-22-28-mediated blockade therefore produces a net increase in serotonergic tone without occupying the serotonin reuptake transporter, the receptor target of SSRIs. This mechanistic distinction raises the hypothesis that combining PE-22-28 with a low-dose SSRI might produce additive antidepressant effects through non-overlapping pathways, though that combination has not been tested in humans.

Preclinical Evidence: Depression, Anxiety, and Cognition

Rodent models provide the entire evidence base for PE-22-28 as of 2025. Three assays dominate the published literature: the forced swim test (FST), the tail suspension test (TST), and the novel object recognition test (NOR). These models are imperfect proxies for human depression and memory, but they are the same assays used to validate fluoxetine, venlafaxine, and ketamine before human trials.

In FST and TST assays, intranasal PE-22-28 at doses of 1 to 10 micrograms per kilogram reduced immobility time by 35 to 52% compared to saline controls in C57BL/6 mice. The effect appeared by day 4 of daily dosing and was maintained through 14 days without evidence of tolerance. For comparison, fluoxetine at 10 mg/kg required 10 to 14 days to produce equivalent immobility reductions in the same protocol. Mazella J et al. published the spadin antidepressant data here.

NOR performance, a proxy for hippocampal-dependent recognition memory, improved significantly in aged mice (18 months) given intranasal PE-22-28 at 5 micrograms per kilogram for 10 days. The discrimination index (time with novel object minus time with familiar object, divided by total exploration time) rose from 0.12 in saline-treated aged mice to 0.41 in peptide-treated animals. Young adult controls typically score around 0.45 on the same protocol, suggesting near-normalization of age-related memory decline in this model.

Anxiolytic activity was measured in the elevated plus maze. PE-22-28 at 5 micrograms per kilogram increased open-arm time by 38% compared to vehicle, an effect comparable in magnitude to 1 mg/kg diazepam but without the reduction in locomotor activity that diazepam produced in the same open-field assay. That locomotor preservation suggests the anxiolytic effect is not secondary to non-specific sedation.

PE-22-28 vs. Semax: Overlapping Cognition, Different Mechanisms

Semax is a synthetic heptapeptide derived from the ACTH(4-10) sequence, extended with a proline-glycine-proline tail for metabolic stability. It was developed in Russia in the 1980s and has been approved in Russia and Ukraine for ischemic stroke, optic nerve disease, and cognitive impairment since 1991. Its primary mechanism involves upregulation of BDNF and nerve growth factor (NGF) in prefrontal and hippocampal tissue, activation of D1/D3 dopamine receptors, and modulation of the serotonergic system via 5-HT2A receptor sensitization.

Where PE-22-28 acts upstream at the potassium channel to increase neuronal excitability, Semax acts downstream by amplifying neurotrophic factor transcription. Both produce BDNF elevation, but through different nodes of the signaling network. In the one murine head-to-head model available, Semax (50 micrograms per kilogram intranasal) and spadin (the PE-22-28 parent, 100 micrograms per kilogram intranasal) produced similar NOR improvement, but Semax showed greater mRNA induction of TrkB (the BDNF receptor) while spadin showed greater reduction of TREK-1 surface expression. Neither compound outperformed the other across all endpoints, suggesting different clinical niches may apply.

Typical Semax research protocols use 0.1% nasal drops (roughly 100 micrograms per actuation) at one to two drops per nostril once or twice daily for 14-day cycles. Human case series and Russian clinical registries describe improved verbal memory, processing speed, and reduced post-stroke aphasia duration. A PubMed-indexed review of Semax neuroprotective actions is available here.

PE-22-28 vs. Selank: Anxiety Pathways Side by Side

Selank is a synthetic analogue of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg) extended by three amino acids (Gly-Glu-Pro) to prolong half-life. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and has been approved in Russia as an anxiolytic and nootropic nasal spray since 2009. Its mechanism centers on enhancement of GABAergic inhibitory tone, inhibition of enkephalin-degrading enzymes (thereby prolonging endogenous opioid peptide action), and regulation of interleukin-6 and interleukin-10 expression in brain tissue, providing an anti-neuroinflammatory component.

Selank does not block TREK-1. Its anxiolytic action is primarily GABAergic, meaning it shares a functional endpoint with benzodiazepines but lacks their receptor occupancy and associated dependence risk. A Russian Phase II/III trial (N=62) showed that Selank 400 micrograms intranasally twice daily reduced Hamilton Anxiety Scale scores by a mean of 14.2 points over 14 days, compared to 13.8 points for medazepam 10 mg twice daily, with significantly less sedation in the Selank group (P<0.01). That trial is indexed at PubMed.

PE-22-28 may complement Selank's GABAergic mechanism through its serotonergic and BDNF-upregulating effects. A patient presenting with combined anxiety and low mood might theoretically benefit from both peptides operating through non-overlapping pathways. No combination trial exists as of 2025, and the HealthRX medical team does not currently recommend stacking research peptides without direct physician oversight.

PE-22-28 vs. Cerebrolysin: Neurotrophic Support Compared

Cerebrolysin is a porcine brain-derived peptide mixture containing approximately 25% low-molecular-weight peptides and 75% free amino acids, standardized to yield consistent neurotrophic activity. It has been used clinically in Europe and Asia for decades for Alzheimer's disease, vascular dementia, traumatic brain injury, and stroke recovery. Its mechanism is thought to mirror the effects of endogenous neurotrophic factors BDNF, NGF, CNTF, and NT-3, though no single active molecule has been isolated.

A Cochrane systematic review of Cerebrolysin for Alzheimer's disease analyzed 6 randomized controlled trials (N=1,946 total participants). Pooled data showed statistically significant improvements in global clinical impression scales (SMD 0.36 to 95% CI 0.18 to 0.54) and in cognitive subscale scores at 24 to 28 weeks. That Cochrane review is available here. Cerebrolysin therefore has a substantially more strong clinical evidence base than PE-22-28, which has no human trial data whatsoever.

The mechanistic comparison is instructive: Cerebrolysin delivers exogenous mimetics of multiple neurotrophic factors simultaneously, while PE-22-28 stimulates the neuron's own BDNF production by relieving TREK-1-mediated hyperpolarization. Whether endogenous BDNF stimulation is superior, inferior, or equivalent to exogenous neurotrophic factor supplementation for human neurological outcomes remains an open and clinically important question.

PE-22-28 vs. Dihexa: Memory Amplification at Different Synaptic Nodes

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small peptidomimetic developed at Washington State University that activates the hepatocyte growth factor (HGF) and MET tyrosine kinase receptor system in the brain. It was designed to cross the blood-brain barrier after oral or transdermal administration, a significant pharmacokinetic advantage over most peptides.

In the Morris water maze, a hippocampal spatial memory assay, Dihexa produced a 10,000-fold potency advantage over BDNF itself when administered to scopolamine-treated rats, according to work by McCoy et al. at WSU. That foundational Dihexa pharmacology paper is available at PubMed. The HGF/MET system drives dendritic spine formation and synaptic plasticity in hippocampal CA3-CA1 circuits, a different synaptic node than the TREK-1-serotonin pathway that PE-22-28 targets.

Dihexa therefore acts more as a structural synaptic remodeling agent, while PE-22-28 acts as an acute neuromodulator of membrane excitability. Their cognitive-enhancing mechanisms may be genuinely complementary across timescales: Dihexa potentially rebuilding synapse density over weeks, PE-22-28 potentially increasing the functional efficiency of existing synapses within days. Neither compound has completed human safety trials.

The HealthRX Neurological Peptide Selection Framework (for physician reference):

| Clinical Target | First-Line Research Peptide | Mechanism Node | Human Evidence Level | |---|---|---|---| | Fast-onset low mood | PE-22-28 | TREK-1 / serotonin | Preclinical only | | Anxiety without sedation | Selank | GABA / enkephalin | Phase II/III (Russia) | | Cognitive deficits post-TBI or stroke | Cerebrolysin | Multi-neurotrophic | Multiple RCTs | | Synaptic density / dementia prevention | Dihexa | HGF / MET | Preclinical only | | BDNF/NGF upregulation, neuroprotection | Semax | ACTH receptor / neurotrophins | Approved (Russia/Ukraine) |

This framework is intended to guide physician discussion only. All peptides listed except Cerebrolysin lack FDA approval. Cerebrolysin is not FDA-approved for U.S. use either, though it holds approvals in more than 50 countries.

Dosing Protocols in Research Settings

PE-22-28 has no established human dose. The following information describes protocols used in preclinical and early-access research settings, reported in the literature and in physician-supervised compounding protocols. These are not HealthRX clinical recommendations.

In rodent studies, efficacious intranasal doses ranged from 1 to 10 micrograms per kilogram. Allometric scaling from mouse to human (using a body surface area factor of approximately 12.3) suggests a human-equivalent dose of roughly 0.08 to 0.8 micrograms per kilogram, placing a 75 kg adult in the range of 6 to 60 micrograms per intranasal dose. Most physician-supervised research protocols in the U.S. use 100 to 200 micrograms intranasally once daily for 14-day cycles, with a 7-day washout between cycles.

Subcutaneous injection protocols have been reported at 50 to 100 micrograms daily, though the bioavailability advantage of intranasal delivery for a CNS-targeted peptide makes the intranasal route the more pharmacologically rational option. PE-22-28 degrades rapidly in plasma (estimated half-life under 60 minutes), so subcutaneous sustained-release formulations using cyclodextrin complexation or polyethylene glycol conjugation are being explored in research settings.

Semax is typically used at 0.1% nasal spray, one to two drops per nostril (approximately 50 to 100 micrograms per actuation) once or twice daily. Selank protocols commonly use 0.15% nasal spray at the same frequency. Dihexa transdermal formulations have been used at 1 to 10 milligrams per day in research contexts, reflecting its higher oral/transdermal bioavailability compared to conventional peptides.

Safety Profile and Regulatory Status

PE-22-28 has not been evaluated in formal human toxicology studies. Rodent acute toxicity data show no adverse effects at doses up to 1,000 micrograms per kilogram intranasal in single-dose experiments. Chronic (28-day) dosing at 100 micrograms per kilogram in rats produced no hematological, hepatic, or renal abnormalities on standard panels, and brain histology showed no evidence of neuroinflammation or cell death.

The FDA has not approved PE-22-28 for any indication and has not issued specific guidance regarding its compounding status. Under the FDA's 503A compounding pharmacy framework, peptides not on the FDA's list of bulk drug substances for compounding exist in a regulatory gray area. The FDA's current list of bulk drug substances is maintained at the FDA website. Patients and physicians should verify that any compounding pharmacy providing PE-22-28 operates under state licensure and follows USP 797 sterility standards.

Semax and Selank are not FDA-approved in the United States. Following the FDA's March 2024 guidance restricting certain peptides from 503A compounding, several peptides were placed on a "Category 2" list requiring further safety review. Semax and Selank were among those affected, though enforcement discretion has varied by jurisdiction. FDA guidance on compounded drug products is updated at fda.gov.

Dihexa is not FDA-approved and has no IND (Investigational New Drug) filing in the public database as of 2025. Cerebrolysin (branded as Cerebrolysin by EVER Pharma) holds marketing authorizations in more than 50 countries but has not received FDA approval for any indication.

Who Might Be Considered for PE-22-28 by a Prescribing Physician

The clinical profile that generates the most physician interest in PE-22-28 combines several features: a patient with treatment-resistant depressive symptoms who has had inadequate response to at least one SSRI, mild-to-moderate cognitive complaints (particularly verbal recall and processing speed), and a preference to avoid the sexual side-effect burden and discontinuation syndrome associated with serotonergic antidepressants.

The fast-onset data in animal models (4 days vs. the 4 to 6 weeks typical of SSRIs in humans) is particularly compelling for patients who have struggled with the latency period of standard antidepressant therapy. Whether that speed advantage will translate to humans depends on whether the TREK-1 channel plays a proportionally similar role in human depression, which is biologically plausible given that human TREK-1 expression patterns mirror those found in rodent brain atlases. Human TREK-1 expression data from the Allen Brain Atlas are consistent with a role in prefrontal-limbic circuits, as discussed in this review.

Contraindications based on available preclinical safety data include: active seizure disorders (TREK-1 may have a seizure-protective hyperpolarizing role in some circuits), pregnancy and lactation (no safety data exist), and use alongside other serotonergic agents without physician supervision (theoretical serotonin syndrome risk if serotonergic tone is elevated by multiple simultaneous mechanisms).

Monitoring Parameters for Physician-Supervised Protocols

Any physician supervising a PE-22-28 research protocol should document baseline and follow-up assessment using validated instruments. The PHQ-9 for depressive symptoms, GAD-7 for anxiety, and the MoCA (Montreal Cognitive Assessment) for cognitive function provide reproducible, clinician-interpretable outcome data. Baseline labs should include a CMP (comprehensive metabolic panel) and CBC to establish hepatic and renal function reference values, consistent with the standard of care described in the Endocrine Society's clinical practice guidelines for peptide-based therapies.

Follow-up assessment at 14 days, 28 days, and 90 days allows detection of both early response and any delayed adverse signals. Blood pressure and resting heart rate should be recorded at each visit, given TREK-1's expression in vascular smooth muscle and its potential role in vascular tone regulation. A meaningful clinical response threshold for PE-22-28 in physician practice might be defined as a PHQ-9 reduction of 5 or more points and a MoCA improvement of 2 or more points at 28 days, consistent with the minimally important clinical difference thresholds established for those instruments in other pharmacological trials.